Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.

Cruickshanks N, Zhang Y, Hine S, Gibert M, Yuan F, Oxford M, Grello C, Pahuski M, Dube C, Guessous F, Wang B, Deveau C, Saoud K, Gallagher I, Wulfkuhle J, Schiff D, Phan S, Petricoin E, Abounader R.

Clin Cancer Res. 2019 Jan 15;25(2):663-673. doi: 10.1158/1078-0432.CCR-18-0926. Epub 2018 Sep 10.

PMID:
30201763
2.

Abiraterone in Metastatic Prostate Cancer.

Ismaili N, Guessous F.

N Engl J Med. 2017 Oct 26;377(17):1695-6. doi: 10.1056/NEJMc1711029. No abstract available.

PMID:
29083124
3.

The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.

Vanderdys V, Allak A, Guessous F, Benamar M, Read PW, Jameson MJ, Abbas T.

Mol Cancer Ther. 2018 Feb;17(2):368-380. doi: 10.1158/1535-7163.MCT-17-0083. Epub 2017 Aug 24.

4.

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.

Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, Slingluff CL Jr, Abbas T.

EBioMedicine. 2016 Aug;10:85-100. doi: 10.1016/j.ebiom.2016.06.023. Epub 2016 Jun 16.

5.

A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival.

Kefas B, Floyd DH, Comeau L, Frisbee A, Dominguez C, Dipierro CG, Guessous F, Abounader R, Purow B.

Neuro Oncol. 2013 Dec;15(12):1652-63. doi: 10.1093/neuonc/not118. Epub 2013 Oct 24.

6.

A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.

Huang X, Zhang Y, Tang Y, Butler N, Kim J, Guessous F, Schiff D, Mandell J, Abounader R.

Neoplasia. 2013 Aug;15(8):952-65.

7.

Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Zhang Y, Farenholtz KE, Yang Y, Guessous F, Dipierro CG, Calvert VS, Deng J, Schiff D, Xin W, Lee JK, Purow B, Christensen J, Petricoin E, Abounader R.

Clin Cancer Res. 2013 Mar 15;19(6):1433-44. doi: 10.1158/1078-0432.CCR-12-2832. Epub 2013 Feb 5.

8.

Oncogenic effects of miR-10b in glioblastoma stem cells.

Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S, Kefas B, Godlewski J, Schiff D, Purow B, Abounader R.

J Neurooncol. 2013 Apr;112(2):153-63. doi: 10.1007/s11060-013-1047-0. Epub 2013 Jan 10.

9.

Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.

Guessous F, Yang Y, Johnson E, Marcinkiewicz L, Smith M, Zhang Y, Kofman A, Schiff D, Christensen J, Abounader R.

Mol Cancer Ther. 2012 Feb;11(2):288-97. doi: 10.1158/1535-7163.MCT-11-0490. Epub 2011 Dec 21.

10.

microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.

Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow B, Abounader R.

Cell Cycle. 2010 Mar 15;9(6):1031-6. Epub 2010 Mar 15.

11.

XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R.

IDrugs. 2010 Feb;13(2):112-21. Review.

12.

An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Guessous F, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D, Buchanan S, Abounader R.

Anticancer Agents Med Chem. 2010 Jan;10(1):28-35.

13.

MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow B, Abounader R.

Cancer Res. 2009 Oct 1;69(19):7569-76. doi: 10.1158/0008-5472.CAN-09-0529. Epub 2009 Sep 22.

14.

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.

Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, Johnson E, Marcinkiewicz L, Engelhardt M, Kefas B, Schiff D, Kim J, Abounader R.

Mol Cancer Ther. 2009 Feb;8(2):376-85. doi: 10.1158/1535-7163.MCT-08-0627. Epub 2009 Feb 3.

15.

Signaling pathways in medulloblastoma.

Guessous F, Li Y, Abounader R.

J Cell Physiol. 2008 Dec;217(3):577-83. doi: 10.1002/jcp.21542. Review.

PMID:
18651559
17.

Integrated optical pickup system for axial dual focus.

Stankovic S, Dias D, Hain M, Bhattacharya S, Glöckner R, Karaboué C, Benmohammadi L, Guessous F, Wang L, Tschudi T, Ferstl M, Pawlowski E, Steingrüber R.

Appl Opt. 2001 Feb 10;40(5):614-21.

PMID:
18357037
18.

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L, Johnson E, Lal B, Hussaini I, Bao Y, Laterra J, Schiff D, Abounader R.

Cancer Res. 2008 Mar 15;68(6):1723-31. doi: 10.1158/0008-5472.CAN-07-1963.

19.

Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma.

Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, Fan S, Lal B, Laterra J, Schiff D, Abounader R.

Lab Invest. 2008 Feb;88(2):98-111. Epub 2007 Dec 3.

20.

Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function.

Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Keepers TR, Obrig T, Gear AR.

Thromb Haemost. 2005 Nov;94(5):1019-27.

PMID:
16366002
21.

Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Kongkhum S, Heatherly D, Obrig T, Gear AR.

Infect Immun. 2005 Dec;73(12):8306-16.

22.

Copper-indomethacinate associated with zwitterionic phospholipids prevents enteropathy in rats: effect on inducible NO synthase.

Bertrand V, Guessous F, Le Roy AL, Viossat B, Fessi H, El Abbouyi A, Giroud JP, Roch-Arveiller M.

Dig Dis Sci. 1999 May;44(5):991-9.

PMID:
10235609
23.

Effect of an encapsulated anti-elastase compound on experimental gingival inflammation in the rat.

Guessous F, el Abbouyi A, Giroud JP, Meyer J, Roch-Arveiller M.

Eur J Clin Chem Clin Biochem. 1997 Nov;35(11):867-71.

PMID:
9426346
24.

Active and alpha-1 proteinase inhibitor complexed leukocyte elastase levels in crevicular fluid from patients with periodontal diseases.

Meyer J, Guessous F, Huynh C, Godeau G, Hornebeck W, Giroud JP, Roch-Arveiller M.

J Periodontol. 1997 Mar;68(3):256-61.

PMID:
9100201
25.

Inhibition of human neutrophil elastase by wheat ceramides.

Bizot-Foulon V, Godeau G, Guessous F, Lati E, Rousset G, Roch-Arveillier M, Hornebeck W.

Int J Cosmet Sci. 1995 Dec;17(6):255-64. doi: 10.1111/j.1467-2494.1995.tb00130.x.

PMID:
19245473
26.

An animal model for the assessment of gingival lesions.

Guessous F, Huynh C, N'Guyen H, Godeau G, Giroud JP, Meyer J, Hornebeck W, Roch-Arveiller M.

J Pharmacol Toxicol Methods. 1994 Nov;32(3):161-7.

PMID:
7858310
27.

Improving feeding systems for sheep in a Mediterranean rain-fed cereals/livestock area of Morocco.

Guessous F, Rihani N, Kabbali A, Johnson WL.

J Anim Sci. 1989 Nov;67(11):3080-6. Review.

PMID:
2687218
28.

[The goat and the utilization of resources in a difficult environment].

Bourbouze A, Guessous F.

Rev Elev Med Vet Pays Trop. 1979;32(2):191-8. French. No abstract available.

PMID:
554278
29.

[Effect of sodium acetate and propionate added to the diet before and after giving birth on the metabolism, production and lipid composition of goat milk].

Guessous F, Fehr PM, Delage J.

Ann Biol Anim Biochim Biophys. 1974;14(2):251-69. French. No abstract available.

PMID:
4458556

Supplemental Content

Loading ...
Support Center